论文部分内容阅读
目的探讨CerbB2和P53在子宫内膜癌中的表达意义以及二者间的关系。方法应用免疫组织化学法回顾性分析了85例子宫内膜癌患者的石蜡标本中CerbB2和P53蛋白的表达,并对其生存期进行随访。结果CerbB2和P53表达的阳性率分别为27.06%、45.88%;CerbB2阳性表达者5年生存率为52.38%,阴性表达者为73.65%,差异有显著意义(P<0.05);P53阳性表达者5年生存率为59.25%,阴性表达者为84.36%,差异有显著意义(P<0.05);CerbB2和P53表达间无相关性。结论CerbB2和P53在子宫内膜癌中的表达与内膜癌的生物学行为有关,可作为子宫内膜癌预后的指标,指导子宫内膜癌术后的治疗。
Objective To investigate the expression of CerbB2 and P53 in endometrial carcinoma and the relationship between them. Methods The expression of CerbB2 and P53 in paraffin specimens from 85 patients with endometrial carcinoma was retrospectively analyzed by immunohistochemistry and the survival was followed up. Results The positive rates of CerbB2 and P53 were 27.06% and 45.88% respectively. The 5-year survival rates of CerbB2 positive and negative ones were 52.38% and 73.65%, respectively (P <0.05) The annual survival rate was 59.25%, the negative expression was 84.36%, the difference was significant (P <0.05); CerbB2 and P53 expression was not related. Conclusion The expression of CerbB2 and P53 in endometrial carcinoma is related to the biological behavior of endometrial carcinoma, which can be used as an index of prognosis of endometrial carcinoma to guide the postoperative treatment of endometrial carcinoma.